Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Cancers|August 29, 2024
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted TherapiesPernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Therapeutic Advances in Medical Oncology|January 25, 2021
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancerPernelle Lavaud, Clément Dumont, Constance Thibault, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|May 20, 2025
Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomographyHenri Leleu, Quentin Berkovitch, Julia Bonastre, et al.
Bulletin Du Cancer|May 28, 2016
[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies]Clément Bonnet, Guillaume Beinse, Luc Cabel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcomeEmeline Colomba, Grégoire Marret, Giulia Baciarello, et al.
Clinical Genitourinary Cancer|May 1, 2020
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 TrialClément Dumont, Giulia Baciarello, Pierre-Olivier Bosset, et al.
The Breast Journal|November 11, 2018
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutationsYoan Ditchi, Chloé Broudin, Yolla El Dakdouki, et al.
JTO Clinical and Research Reports|February 24, 2025
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance MechanismsArianna Marinello, Claudia Parisi, Damien Vasseur, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2026
Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancerDanny Lavigne, Cecile Le Péchoux, Angela Botticella, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Pageof 6